{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:19Z","timestamp":1792611679023,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.contraception.2022.01.018","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T21:16:48Z","timestamp":1643923008000},"page":"6-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel"],"prefix":"10.1016","volume":"110","author":[{"given":"Ingrid J.M.","family":"Duijkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-0063","authenticated-orcid":false,"given":"Christine","family":"Klipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Schug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithi S.","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Osterwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oettel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.contraception.2022.01.018_bib0001","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/0010-7824(94)90113-9","article-title":"Progestin-only oral contraception: a comprehensive review","volume":"50","author":"McCann","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0002","series-title":"Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone","year":"2015"},{"key":"10.1016\/j.contraception.2022.01.018_bib0003","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0015-0282(16)39255-X","article-title":"Morphologic changes in the ovaries of women treated with continuous microdose progestogens","volume":"23","author":"Moghissi","year":"1972","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2022.01.018_bib0004","first-page":"585","article-title":"Contraceptive mechanism of microdose norethindrone","volume":"41","author":"Moghissi","year":"1973","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0010-7824(79)80038-4","article-title":"Hormonal effects of the 300 \u00b5g` norethisterone (NET) minipill. 2. Daily gonadotropin levels in 43 subjects during a pretreatment cycle and during the second month of NET administration","volume":"20","author":"Landgren","year":"1979","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0006","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0010-7824(80)90142-0","article-title":"Hormonal effects of the 300 \u00b5g norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration","volume":"21","author":"Landgren","year":"1980","journal-title":"Contraception"},{"issue":"Suppl 88","key":"10.1016\/j.contraception.2022.01.018_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/00016347909157223","article-title":"Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations","author":"Spona","year":"1979","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2022.01.018_bib0008","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/oxfordjournals.humrep.a019245","article-title":"Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses","volume":"11","author":"Rice","year":"1996","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2022.01.018_bib0009","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1177\/0091270011423664","article-title":"Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women","volume":"52","author":"Klipping","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0010","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/humrep\/14.4.982","article-title":"A comparison of the inhibition of ovulation achieved by desogestrel 75 \u00b5g and levonorgestrel 30 \u00b5g daily","volume":"14","author":"Rice","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2022.01.018_bib0011","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/13625187.2015.1044082","article-title":"A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24\/4 regimen","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2022.01.018_bib0012","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/13625189809167250","article-title":"A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 \u00b5g\/day or levonorgestrel 30 \u00b5g\/day","volume":"3","year":"1998","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2022.01.018_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0010-7824(75)90086-4","article-title":"Initial clinical studies of intravaginal rings containing norethindrone and norgestrel","volume":"12","author":"Mishell","year":"1975","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0010-7824(79)90089-1","article-title":"First year clinical experience with six levonorgestrel rods as subdermal contraception","volume":"20","author":"Faundes","year":"1979","journal-title":"Contraception"},{"issue":"Special Issue 1","key":"10.1016\/j.contraception.2022.01.018_bib0015","first-page":"1","article-title":"The Progestin-Only Pill (POP) is not a niche option: new preclinical and clinical data about the interrelations between levonorgestrel-dose, peripheral as well as central contraceptive effects and bleeding behaviour","volume":"12","author":"Oettel","year":"2015","journal-title":"J Reproduktionsmed Endokrinol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","article-title":"Ultrasound evaluation of ovarian activity under oral contraceptives","volume":"47","author":"Hoogland","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0017","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0010-7824(01)00226-8","article-title":"Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants","volume":"64","author":"Sivin","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.contraception.2018.04.007","article-title":"Phase I\/II pharmacokinetic and pharmacodynamic evaluation of two levonorgestrel-only contraceptive patches in a multicenter randomized trial","volume":"98","author":"Westhoff","year":"2018","journal-title":"Contraception"},{"issue":"S","key":"10.1016\/j.contraception.2022.01.018_bib0019","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","article-title":"Classification and pharmacology of progestins","volume":"46","author":"Schindler","year":"2003","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2022.01.018_bib0020","series-title":"Kontrazeption mit Hormonen, ein Leitfaden f\u00fcr die Praxis","first-page":"84","author":"Taubert","year":"1995"},{"key":"10.1016\/j.contraception.2022.01.018_bib0021","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0010-7824(99)00028-1","article-title":"Timing of onset of contraceptive effectiveness in Norplant\u00ae implant users","volume":"59","author":"Brache","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0022","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0023","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1038\/psp.2012.10","article-title":"Integrated pharmacometrics and systems pharmacology model-based analysis to guide GnRH receptor modulator development for management of endometriosis","volume":"1","author":"Riggs","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0024","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-019-05103-6","article-title":"Bone health in estrogen-free contraception","author":"Hadji","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.contraception.2022.01.018_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0010-7824(92)90148-M","article-title":"Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle","volume":"46","author":"Kuhnz","year":"1992","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2022.01.018_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/13625187.2020.1815008","article-title":"Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration route","volume":"25","author":"Hofmann","year":"2020","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2022.01.018_bib0027","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.contraception.2017.01.004","article-title":"Pharmacokinetics of levonorgestrel and ulipristal acetate emergency contraception in women with normal and obese body mass index","volume":"95","author":"Praditpan","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0028","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.contraception.2014.11.001","article-title":"Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception","volume":"91","author":"Kapp","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0029","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s00404-019-05340-4","article-title":"A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg","volume":"300","author":"Palacios","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.contraception.2022.01.018_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2008.02.019","article-title":"Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24\/4 regimen","volume":"78","author":"Klipping","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.01.018_bib0031","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/AOG.0b013e3181eb6b0f","article-title":"Using daily text-message reminders to improve adherence with oral contraceptives: a randomized controlled trial","volume":"116","author":"Hou","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.01.018_bib0032","unstructured":"Committee for Medicinal Products for Human Use. Guideline on bioanalytical method validation. EMEA\/CHMP\/EWP\/192217\/2009 Rev.1 Corr. 2 (2011)."},{"key":"10.1016\/j.contraception.2022.01.018_bib0033","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Bioanalytical method validation. Guidance for industry (2018)."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:12:11Z","timestamp":1762117931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782422000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"alternative-id":["S0010782422000245"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2022.01.018","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2022.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}